Lates News

According to AI Express, Huayuan Securities released a research report on November 10, giving Jinbo Biotech (920982.SH) a "buy" rating. The main reasons for the rating include: 1) the company's injection-type A-type recombinant human collagen protein products as the basic plate, functional skincare products bring additional volume; 2) the company actively responds to the demand of China's health industry, and its private placement has been accepted by the stock exchange. (Daily Economic News)